In modern medicine, chronic kidney disease (CKD) has become a global public health issue. Among them, renal dialysis, as one of the main treatment methods for late stage CKD, plays a key role in relieving patients' pain and delaying the progression of the disease. However, as dialysis treatment progresses, a common complication - anemia - increasingly highlights its severity and scope of impact. Anemia not only reduces the quality of life of patients, but may also increase their cardiovascular burden and affect prognosis. Therefore, effective management of anemia in dialysis patients is crucial. This article will explore the mechanism and diagnostic criteria of anemia in dialysis patients, as well as the application of drugs such as iron and erythropoietin (EPO) in anemia management.
1、 The mechanism of anemia
1. Anemia caused by renal failure: One of the main functions of the kidneys in the body is to promote the production of red blood cells by releasing erythropoietin (EPO) to stimulate the bone marrow to produce red blood cells. However, in chronic kidney disease, kidney function is impaired and EPO production is inhibited, leading to the occurrence of anemia.
2. Iron metabolism disorder: In addition to insufficient EPO, kidney disease can also lead to iron metabolism disorders, including problems with iron absorption, transport, and utilization, thereby exacerbating anemia.
3. Chronic inflammatory response: In CKD patients, the normal physiological process of erythropoiesis is disrupted due to increased release of inflammatory factors, which is also an important cause of anemia.
4. The impact of hemodialysis itself: During hemodialysis, the loss of blood and the action of dialysis membranes may also cause anemia.
2、 Diagnostic criteria for anemia
According to the recommendations of KDIGO (Global Practice Guidelines for Chronic Kidney Disease), anemia in dialysis patients is generally diagnosed with hemoglobin (Hb) levels below 110g/L. However, for certain high-risk populations, such as elderly patients or those with concomitant cardiovascular disease, this criterion can even be appropriately raised.
In addition, it is necessary to consider the patient's symptoms and signs, such as fatigue, dizziness, palpitations, as well as other related examination indicators, such as red blood cell count, hematocrit, etc., to comprehensively evaluate the severity of anemia.
3、 Application of Iron Agents in Dialysis Patients
1. Types of Iron Agents: Currently, commonly used iron agents include oral iron agents and intravenous iron agents. Oral iron supplements mainly include ferrous sulfate, ferrous gluconate, etc., and are suitable for patients with mild to moderate anemia. Intravenous iron supplements mainly include iron gluconate, iron gluconate sucrose complex, etc., which are suitable for patients with severe anemia or ineffective oral iron supplements.
2. Principles for selecting iron supplements: When choosing iron supplements, factors such as the patient's anemia level, iron reserves, and tolerance should be considered. Oral iron supplements have the advantages of convenience and affordability, but may lead to gastrointestinal adverse reactions; The effect of intravenous iron is more rapid and significant, but the cost is higher and there are risks such as allergies.
3. Monitoring of iron therapy: During iron therapy, it is necessary to monitor the patient's iron metabolism indicators, such as serum iron and transferrin saturation, to guide the adjustment of treatment plans.
4、 Application of erythropoietin in dialysis patients
1. Mechanism of action of erythropoietin: Erythropoietin (EPO) is a hormone that stimulates the proliferation and differentiation of immature red blood cells in the bone marrow, promoting the generation of red blood cells.
2. Indications for EPO application: Common indications for EPO application in dialysis patients include renal anemia, dialysis related anemia, etc. For renal anemia, EPO treatment can significantly increase the patient's Hb level, improve anemia related symptoms, enhance quality of life and physical activity level; For dialysis related anemia, EPO treatment can help reduce the need for blood transfusions, lower the incidence of cardiovascular events, and improve prognosis.
3. Precautions for EPO treatment: When using EPO treatment, it is necessary to closely monitor the patient's Hb level and blood pressure to avoid adverse reactions caused by high or low Hb, such as thrombosis and cardiovascular events. In addition, for patients with iron metabolism disorders, it is necessary to use iron supplements in combination to improve the efficacy of EPO.
4. Dose adjustment of EPO treatment: The dose of EPO treatment should be adjusted according to the specific situation of the patient, including factors such as age, gender, dialysis method, and comorbidities. Generally speaking, the initial dose can be determined based on the patient's weight and Hb level, and then gradually adjusted according to treatment response and side effects.
5、 Comprehensive treatment strategy
1. Individualized treatment plan: Anemia management should be individualized, and corresponding treatment plans should be developed based on the specific situation and severity of the patient's condition. This requires comprehensive consideration of factors such as the patient's age, gender, renal function, and comorbidities, and close monitoring of the patient's response and changes in indicators during the treatment process.
2. Combined use of iron and EPO: For dialysis patients with iron metabolism disorders, the combined use of iron and EPO can improve treatment efficacy and reduce the occurrence of adverse reactions. When formulating a joint application plan, it is necessary to make reasonable adjustments based on the specific situation of the patient and iron metabolism indicators.
3. Lifestyle management: In addition to medication treatment, appropriate lifestyle management is also crucial for improving anemia. Including a balanced diet and increasing intake of iron rich foods such as red meat, animal organs, beans, etc; Maintain an appropriate amount of exercise to promote blood circulation and oxygen delivery.
Conclusion
Anemia management in dialysis is a complex issue that involves multiple causes and treatment methods. Effective management of anemia can not only improve patients' quality of life, but also reduce their cardiovascular burden, delay disease progression, and improve prognosis. Iron supplements and erythropoietin are important drugs for treating anemia, and their application in dialysis patients is of great significance. However, it should be noted that anemia management should be individualized, and corresponding treatment plans should be developed based on the specific situation of the patient. During the treatment process, the patient's response and changes in indicators should be closely monitored to achieve the best treatment effect. I hope that through the introduction in this article, we can increase our understanding of anemia management during dialysis and provide some reference and guidance for clinical practice.